Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of ALV003 for the Treatment of Celiac Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* History of biopsy-proven celiac disease~* Adherence to a gluten-free diet~* TG2 antibody negative~* Signed informed consent~Exclusion Criteria:~* Active dermatitis herpetiformis~* History of IgE-mediated reactions to gluten~* Use of specific medications 6 months prior to entry~* History of alcohol abuse or illicit drug use~* Current untreated or GI disease~* Positive pregnancy test~* Received any experimental drug within 14 days of randomization~* Uncontrolled chronic disease or condition~* Uncontrolled complications of celiac disease~* Any medical condition, which could adversely affect participation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- ALV003 (Type: EXPERIMENTAL): ALV003 is an orally administered mixture of two recombinant proteases (cysteine endoprotease B-isoform 2 and prolyl endopeptidase) engineered to degrade gluten into non-immunogenic fragments, by targeting the glutamine and proline residues common in gluten.
- Placebo comparator (Type: PLACEBO_COMPARATOR): Excipients for ALV003 absent the experimental compounds

Based on this trial design, predict the completion outcome and termination type (if applicable).